Royal Bank of Canada’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7,079
| Closed | -$68K | – | 7403 |
|
|
2024
Q4 | $68K | Sell |
7,079
-613
| -8% | -$3.2K | ﹤0.01% | 5542 |
|
|
2024
Q3 | $22K | Buy |
7,692
+8
| +0.1% | +$25 | ﹤0.01% | 6081 |
|
|
2024
Q2 | $23K | Buy |
7,684
+4,865
| +173% | +$13.3K | ﹤0.01% | 6025 |
|
|
2024
Q1 | $9K | Sell |
2,819
-20,551
| -88% | -$68.5K | ﹤0.01% | 6259 |
|
|
2023
Q4 | $79K | Buy |
23,370
+10,663
| +84% | +$27.5K | ﹤0.01% | 5757 |
|
|
2023
Q3 | $30K | Buy |
12,707
+4,401
| +53% | +$9.22K | ﹤0.01% | 6033 |
|
|
2023
Q2 | $14K | Buy |
8,306
+5,911
| +247% | +$15.1K | ﹤0.01% | 6363 |
|
|
2023
Q1 | $8K | Buy |
2,395
+711
| +42% | +$4.26K | ﹤0.01% | 6432 |
|
|
2022
Q4 | $9K | Sell |
1,684
-3,998
| -70% | -$18.3K | ﹤0.01% | 6586 |
|
|
2022
Q3 | $20K | Buy |
5,682
+3,028
| +114% | +$10K | ﹤0.01% | 6152 |
|
|
2022
Q2 | $7K | Sell |
2,654
-312
| -11% | -$867 | ﹤0.01% | 6542 |
|
|
2022
Q1 | $13K | Sell |
2,966
-3,007
| -50% | -$13.6K | ﹤0.01% | 6850 |
|
|
2021
Q4 | $41K | Buy |
5,973
+3,343
| +127% | +$22.8K | ﹤0.01% | 6489 |
|
|
2021
Q3 | $20K | Buy |
2,630
+661
| +34% | +$5.67K | ﹤0.01% | 6714 |
|
|
2021
Q2 | $20K | Sell |
1,969
-1,179
| -37% | -$10.6K | ﹤0.01% | 6574 |
|
|
2021
Q1 | $30K | Buy |
3,148
+2,409
| +326% | +$23.6K | ﹤0.01% | 6202 |
|
|
2020
Q4 | $8K | Buy |
+739
| New | +$7.79K | ﹤0.01% | 6494 |
|
Other funds holding PSTX
Royal Bank of Canada's PSTX Position: Q1 2025 in Review
Royal Bank of Canada sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 7,079 shares — an estimated $68K sold.
Royal Bank of Canada first reported a position in PSTX in Q4 2020 and held it in 17 quarters. The position peaked at $79K in Q4 2023. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Royal Bank of Canada reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Royal Bank of Canada sold 7,079 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $68K.
- Royal Bank of Canada first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2020 and held it in 17 quarters.
- Royal Bank of Canada's Poseida Therapeutics, Inc. Common Stock position peaked at $79K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.